Potential greater therapeutic benefits need to be confirmed with comparative clinical studies.
Introduction
The efficacy of electrophysical agents (EPAs) used in therapy practice is underpinned by their ability to influence the body's physiological mechanisms, thereby affecting the underlying pathological processes. Ultimately, this can lead to effects such as reduction in pain and inflammation, acceleration of tissue healing and overall improvements in function (1, 2) . Several of these benefits relate to thermophysiological responses in the body such as changes to blood flow, muscle tone and tissue compliance achieved primarily through induced tissue hyperthermia (3) (4) (5) (6) .
The physical nature and metabolic state of tissues can be altered by changes in blood flow and tissue extensibility, and thereby provide the therapeutic benefits either directly or create a tissue environment that enables the clinician to deliver treatment more effectively in patients and in non-clinical situations (such as in an athlete recovering from muscle fatigue). For example, increasing the compliance of tight soft tissue structures will enable the therapist to stretch them more effectively and gain improved range of movement (7, 8) . Increasing muscle blood flow may potentially aid faster recovery from post exercise fatigue. In physiotherapy, radiofrequency (RF)-based EPAs are among those that claim to increase blood flow as well as improve soft tissue compliance, mainly by inducing tissue hyperthermia (9) (10) (11) (12) (13) (14) (15) . Measures relating to blood flow and tissue compliance closely reflect the body's response when tissues are exposed to heat, with the radiofrequency energy potentially capable of inducing a hyperthermic effect at depth (16) (17) (18) .
Abnormalities in blood flow have an overarching relationship to pathological states and their treatment; hence an accurate measurement of blood flow without interfering with the circulatory process itself is imperative. A relative change in the local blood flow can characterise a variety of physiological states, either normal or pathological. For example, an increase in local blood flow may be noticed when there is tissue inflammation (19, 20) . When localised radiofrequency treatment is administered, monitoring of the blood flow can help in determining how much heating will occur in the tissues. Hence, it enables a protective regulatory mechanism ensuring that there is no undue tissue hyperthermia (21, 22) .
The RF frequency ranges used in physiotherapy are largely limited to 30 kHz-30 MHz (23) (24) (25) (26) . Within this range the main EPA used is shortwave therapy (SWT), which commonly operates at 27.12 MHz, either in continuous (CSWT) or pulsed (PSWT) mode although it is 4 largely limited to PSWT in contemporary practice (25, 27) . SWT is also the most widely researched radiofrequency-based EPA. Nonetheless, EPAs employing significantly lower frequency RFs (<1 MHz) have also been reported in therapy practice, despite their evidence base being minimal. An example for such an EPA is Capacitive Resistive Monopolar Radiofrequency (CRMRF) that employs radiofrequency at 448 kHz. This mode of therapy is relatively new, but is reported to be available and used by clinicians worldwide as a safe form of electrophysical therapy. Similar to SWT, the particular frequency employed relates to international guidelines rather than reported optimum efficacy.
The CRMRF differs from SWT mainly in two ways -firstly the operating frequency, which is significantly smaller than the shortwaves and secondly, unlike SWT it cannot be delivered to the target tissues through an air gap. Hence, a coupling medium similar to ultrasound gel that acts as a conductor is used to transmit the energy. The inability of CRMRF to transmit through air may act as a potential advantage over SWT since scattering of the CRMRF waves will be considerably lower. Without the need for a special conducting medium, shortwave devices are known to emit stray radiations in the air (1, 28) . Therefore some of the shortwave energy will be lost through scattering, making it difficult to concentrate the delivery in the required area treated (29, 30) .
In this study the authors aimed to investigate the deep blood flow and tissue extensibility responses to continuous-mode CRMRF therapy in asymptomatic adults and compare them to those obtained with PSWT. Similar studies involving only SWT that were conducted on either asymptomatic subjects (12, 14, 15, 31) or patient groups (10, 32, 33) have been reported previously. However, to our knowledge this will be the first in vivo study that investigated the deep physiological responses to RF exposure below the shortwave frequency band.
Although CRMRF is a continuous mode therapy unlike PSWT, comparison of these two EPAs was done on the basis that PSWT is the most relevant comparator to CRMRF in contemporary therapy environment. The clinical use of CSWT has decreased significantly in the western world over the recent decades (25, 27) . Currently, no data is available from the literature comparing the two EPAs. Since CRMRF was shown to substantially increase and sustain skin temperature in our previously reported study (16) , it was hypothesised that similar significant effects may be obtained on deep blood flow and tissue extensibility. The 5 results of this study are expected to provide important insight into the mode of action of low frequency RF-based EPAs such as CRMRF that has largely remained unexplored (23, 26) .
Materials and Methods

Study design
The aims of the study were investigated in a crossover study conducted in the physiotherapy research laboratory of the University of Hertfordshire on 17 asymptomatic (self-reported) adults.
Sample and groups
The participants were randomly recruited via emails from the 27,000 members of the University of Hertfordshire. They all had normal skin thermal perception and no contraindications to radiofrequency-based therapy. Each of the 17 participants attended four sessions using a randomised crossover design, representing four experimental conditions -CRMRF high (thermal), CRMRF low (sub/minimally thermal) and CRMRF placebo dose conditions, and a control condition with no intervention (Figure 1 ). The order of attendance was randomised using a computer generated randomisation chart (IBM SPSS Statistics, Version 20), and concealed blinded from the participants. Fifteen participants additionally attended a fifth session representing 'PSWT high dose' condition to enable a comparison between the two EPAs. Attendance to PSWT condition was not randomised, and hence not truly blinded although they were only informed that it was another type of RF. The study was approved by the Health and Human Sciences Ethics Committee with Delegated Authority (HHSECDA) of the University of Hertfordshire (Protocol number: cHSK/PG/UH/00143). All participants signed an informed consent prior to the study. **Insert Figure 1 here**
Apparatus
CRMRF device
The CRMRF energy at 448 kHz was delivered using 'Indiba Activ 902' (Indiba S. A., Barcelona). This therapeutic device was factory calibrated and pretested for accuracy of output. The peak power of the device was 200 Watts (W) (or 450 Volt-Ampere (VA)). It 6 delivers continuous-wave radiofrequency energy in two modes: A 'capacitive (CAP) mode' and a 'resistive (RES) mode', using metallic electrodes via a coupling medium.
PSWT device
PSWT was delivered using 'Bosch Ultramed' (Robert Bosch GmbH, Germany) that operates at 27.12 MHz. The pulse duration (PD) was fixed at 400 µs, repeating at (pulse repetition rate; PRR) 15-200 Hz. The peak power (PP) can be varied from 100 to 1000 Watts (W). The desired mean power (MP) can be obtained by manipulating these pulse parameters. The device was calibrated prior to the study.
Doppler ultrasound and Sonoelastography
Blood flow to the deeper tissues (two centimetres or more from the skin) was monitored using Doppler ultrasound that provided information on the velocity, volume and intensity of 
Other devices
Blood pressure (BP) and pulse rate (PR) were monitored using a digital BP monitor (Omron M2, Omron Healthcare Europe B.V., Netherlands) and core temperature using an infra-red (IR) tympanic thermometer (Braun ThermoScan IRT 4520, Braun GmbH, Germany). A body composition monitor (Omron BF508, Omron Healthcare Europe B.V., Netherlands) was used to obtain the anthropometric data. Room temperature and humidity were monitored using an electronic thermohygrometer (RS 212-124, RS Components Pte Ltd., Singapore).
Experimental procedure and Data acquisition
The participants were asked to avoid food, beverages and strenuous exercises before the start of sessions to minimise physiological inconsistencies. They attended one treatment condition per session in a random order. A minimum gap of 48 hours was ensured between sessions.
Similar times (±1 hour) of the day were chosen for all sessions of a participant. The 7 participants were screened using an eligibility questionnaire including questions relating to any recent injury or illness and accepted contraindications to RF therapy (pregnancy, malignancy, metal or electronic implants in the body). Subsequently, their 'skin thermal sensitivity' and the ability to distinguish between warm and cold was tested using test tubes filled with water at approximately three different temperatures (±0. For all participants, the machine settings remained the same for both pre and post treatment measurements. Data clips were recorded up to five seconds for both Doppler and Sonoelastography measurements during each assessment, which were then broken down into image frames for analysis. Prior to this study, intra-rater reliability for both Doppler and Sonoelastography measurements was established in a pilot study on 12 participants. The ICCs (3,1) for all measurements relating to blood flow (Doppler) were 0.818 -0.987 with 95% CI, and within 0.957 -0.998 with 95% CI for all measurements relating to tissue compliance (Elastography).
Radiofrequency Intervention
8
The CRMRF treatment was delivered for 15 minutes (5 minutes in CAP mode followed by 10 minutes in RES mode) using 20 ml coupling medium for each mode. The return plate electrode was smeared with 20 ml coupling medium and positioned under the calf muscle belly. The dosage was adjusted based on participant feedback. For CRMRF high, the intensity was gradually increased till the participants reported moderate yet comfortable heating, which was then maintained throughout the session. For CRMRF low, the intensity was maintained at a sub/minimally-thermal level throughout. For CRMRF placebo, the device output was turned off after the participants reported thermal onset (within the first minute). For the control condition the participants rested on the treatment plinth for 15 minutes. The nearest available PSWT dose to the mean CRMRF high dose (42.37 W) used in this study was 47 W (PD-400 µs, PRR-200 Hz, PP-600 W). Hence, 47 W was delivered for 15 minutes to all 15 participants who attended PSWT group, using a drum (monode) applicator placed 1.5 cm from the skin.
Data Analysis
Ultrasound images were computationally analysed using MATLAB (MathWorks, Massachusetts) algorithms to process the colour image data into numerical data. For every image frame the MATLAB algorithms generated two types of data: the 'pixel count' (total number of coloured pixels) in the 'region of interest' (ROI) indicating the blood volume information, and the 'colour intensity index' (sum of colour intensity values of all the coloured pixels in the ROI). In the final analysis, the pixel count was expressed in 'kilo pixels' (pixel count divided by 1000) and the colour intensity index as the 'mean colour intensity index per pixel' by dividing the sum of colour intensity values of a frame by the total number of pixels in that frame. In colour Doppler, the 'colour intensity index' indicated the relative velocity of blood flow, where higher the index higher was the velocity. In power Doppler, the pixel count represented the overall 'blood volume' and the colour intensity index represented the 'blood flow intensity'. Higher the pixel count and/or index, higher were the blood flow. The degree of tissue compliance (level of hardness/softness) data from Sonoelastography was analysed similarly to the Doppler data although the MATLAB algorithms varied depending on the machine colour scales and their pixel values. The analysis of all machine colour scales using MATLAB is further illustrated in Figure 3 .
All data were analysed using IBM SPSS Statistics ((Version 20) IBM Corporation, USA).
Two separate data analyses, with three CRMRF and control groups (17 participants) and with all five groups (15 participants) were undertaken. The data sets from all five experimental conditions were tested for normal distribution. To ascertain any statistically significant differences between conditions, group data were compared using either two-way (intervention and time) repeated measures analysis of variance (ANOVA) at two time points (baseline, post treatment) or using the non-parametric alternative Friedman's two-way ANOVA by ranks, where the data sets violated the assumptions of normality (Shapiro-Wilk test). Statistical significance was set at p ≤ 0.05 (0.8 P, 95% CI). A post-hoc analysis was conducted using G*Power (Version 3.1) to determine the power. **Insert Figure 3 here**
Results
All participants completed the treatments and the accompanying assessments. Both types of interventions were well tolerated, with no reports of any adverse events. The demographic and mean (SD) anthropometric data are reported in Table 1 . Mean (SD) treatment doses, room temperature and humidity are reported in Table 2 . The study was conducted in thermoneutral conditions. To illustrate the levels of variation among participants, the individual dosage data from the three radiofrequency groups are plotted in Figure 4 . **Insert Table 1 here** **Insert Table 2 Table 3 .
**Insert Table 3 Table 4 .
**Insert Table 4 here**
Blood Flow Velocity and Tissue Extensibility
No significant main effects, interactions or changes within groups were noted for any of the intervention groups for any time point in either the four or the five-group analysis for blood flow velocity and the tissue extensibility measures.
Other results
No significant variations were ever noted in core temperature, BP or PR under any test condition.
The post-hoc analysis revealed that the overall power obtained for both statistical analyses on blood flow volume and intensity were over 80%.
Discussion
Although numerous studies have investigated the effects of radiofrequency-based treatment in animal models as well as in humans, there is insufficient evidence to demonstrate the effects of radiofrequency below the shortwave frequency band. Two recent reviews on the use of radiofrequency-based EPAs in therapy-related clinical practice published by the same authors found no clinical studies on acute conditions for frequencies below shortwave (23) and only a limited number of such studies on chronic conditions (26) . The current study addressed the issue of physiological effects of both types of frequency ranges of RF by performing due comparisons between CRMRF that operates at 448 kHz in continuous mode and PSWT that operates at 27 MHz in pulsed mode.
Recently, the skin thermal responses to incremental doses of CRMRF were reported by us in an experimental study (16) . The current study reports other thermophysiological responses such as changes in deep blood flow as well as changes in tissue compliance (up to over two cm depths from the skin), in response to the application of multiple doses of CRMRF therapy and a comparable high dose of PSWT. In terms of the mode of energy delivery PSWT may not be directly comparable to CRMRF since the former is pulsed while the latter is continuous. Besides, PSWT is not known to cause extremely high thermophysiological responses due to a "washout" of the heat energy from the tissues during its "off cycle".
However, the comparisons have been made for the aforementioned reasons. substantial rise in tissue temperature may not be required for CRMRF to achieve increased deep blood flow. Moreover, it needs to be taken into account that the Doppler measurements were only able to be recorded about five minutes after the end of the intervention owing to the skin preparation time and the time taken to locate blood flow, which meant that any blood flow responses during and immediately after the treatment were not accounted for. Therefore, based on the current and previously reported (16) results on CRMRF and the existing shortwave literature (36) , it is proposed that unlike SWT the CRMRF may be capable of increasing and sustaining blood flow at depth at substantially lower tissue temperatures. This suggests that CRMRF is potentially capable of inducing a sustained influence on the physiological processes relating to deep blood flow with mechanisms that are either thermal or nonthermal or both.
13
Considering the above argument, it is implied that compared to CRMRF a substantially higher dose of treatment and hence a substantially higher amount of energy (potentially generating a high thermal response as explained) may be needed for PSWT to produce effects similar to that of CRMRF. In other words, PSWT may lack any notable nonthermal effect on deep blood flow in the absence of significant tissue heating. This is justified by the mixed reports on the deep circulatory effect of PSWT available from the literature (15, 37) , which indicate that when compared to the doses in this study; a substantially higher dose of PSWT may be required to increase blood flow at depth. In fact, PSWT was designed to deliver pulsed RF energy to provide physiological benefits without an undue rise in tissue
temperature. It appears from the results of this study that a low dose CRMRF can potentially achieve the same benefits more effectively than PSWT without unduly raising the tissue temperature despite being a continuous-mode RF therapy. It is therefore assumed that the type of applied energy might also be a critical factor beside the temperature change, in deciding the level of tissue response.
With regards to tissue extensibility, early work has shown that heat changes the behaviour of collagenous tissues making it more viscoelastic (38, 39) , and reduces spasm in muscles (40) .
However, for a notable effect, the tissue temperature will need to be raised at least to the level of 40 o C (41). Contrary to blood flow, there were no significant effects on tissue extensibility with any of the interventions in this study. Nonetheless, it may be noted that the Sonoelastography measurements were performed after the blood flow measurements were taken, thus any effect during or immediately after the intervention should clearly have been missed. This clearly is a limitation of this study. Besides, all participants in this study had normal muscle tone with no concomitant injury. People affected by conditions that may be compromising their tissue extensibility, or even asymptomatic people who are presented with increased tone in their muscles could behave differently to the subjects of this study.
The results also indicate a dose-response relationship, with the high dose CRMRF inducing a more pronounced physiological response than the low dose CRMRF. The mean dose delivered to the high dose group was twice as that of the low dose group. In addition, there were small variations in dosage within the groups itself as a fixed dose was not delivered to every participant in the group (dosing varied based on the participants' thermal perception and thermal tolerance). Since only two active doses of CRMRF were employed, recommendations on the optimum dosage parameters could not be identified. It has also not been possible to identify why some participants were able to receive a higher dose of
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CRMRF when compared to the others. It is proposed that the thermal sensory perception of the individual may have been responsible for the level of energy uptake. The thermal perception is a normally distributed phenomenon in a normative sample. Additional studies will need to be carried out to further identify the dosage and other intervention parameters.
Although the study used a crossover design employing participants with a wide age range (25-66 years, with a mean (SD) age of 45.71 (12.70) years) and varying physical activity levels, there were several study limitations too. Besides the short delay in obtaining the post treatment data, there were no follow-up assessments and the physiological responses during the intervention phase were not mapped, unlike in some of the previous shortwave studies (13, 14, 37) where peripheral blood flow was monitored during the intervention. The PSWT session was not randomised, not fully blinded and was always the fifth session for all participants. Also, the study was only single-blind as the researcher (BK) who performed the interventions and assessments remained unblinded. Together, the above factors may somewhat limit the validity of the findings. Future studies should be fully randomised, double-blinded, employ follow-ups and minimise the time delay in starting the post treatment measurements. Additionally, to facilitate a full understanding of the physiological responses, the measurements should be enabled during the treatment delivery where possible.
Conclusions
The results of this study suggest that a high as well as low dose of CRMRF can significantly enhance blood flow volume at depth, while only the high dose can enhance both the volume and intensity of flow. An equivalent high dose of PSWT failed to show any impact on either parameter, which meant that overall CRMRF induced a significantly more pronounced physiological response out of the two types of radiofrequency-based EPAs. None of the treatment conditions had any impact on the deep blood flow velocity. The extensibility of tissues (relative hardness and softness), core temperature, BP and PR were not affected by either type of RF treatment.
Based on the presented results the hypothesis proposed on the effects of CRMRF on deep blood flow was accepted, but not for tissue extensibility. The more pronounced physiological effects of CRMRF in healthy participants compared to PSWT may be indicative of its potentially greater clinical benefits; however, caution should be exercised in extrapolating these findings to patient populations who could respond differently to the same intervention. The PSWT group results are based on 15 participants, while the other four groups' results are based on 17 participants. Statistically significant differences (at p ≤ 0.05) when the groups were compared pairwise are given in Table 4 (Friedman's two-way ANOVA). 
